filings.toolsItem 16. Form 10-K Summary.
7K characters. Original on sec.gov · Markdown
Item 16. Form 10-K Summary.
None.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on December 6, 2024.
THE COOPER COMPANIES, INC.
By: /s/ Albert G. White, III
Albert G. White, III
President & Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Albert G. White, III, Brian G. Andrews, and Nicholas S. Khadder, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on the dates set forth opposite their respective names.
| Signature | Capacity | Date | ||||||||||||
| /s/ ALBERT G. WHITE, III | President, Chief Executive Officer and Director (Principal Executive Officer) | December 6, 2024 | ||||||||||||
| (Albert G. White, III) | ||||||||||||||
| /s/ ROBERT S. WEISS | Chairman of the Board | December 6, 2024 | ||||||||||||
| (Robert S. Weiss) | ||||||||||||||
| /s/ WILLIAM A. KOZY | Vice Chairman of the Board and Lead Director | December 6, 2024 | ||||||||||||
| (William A. Kozy) | ||||||||||||||
| /s/ BRIAN G. ANDREWS | Executive Vice President, Chief Financial Officer and Treasurer | December 6, 2024 | ||||||||||||
| (Brian G. Andrews) | (Principal Financial Officer) | |||||||||||||
| /s/ AGOSTINO RICUPATI | Senior Vice President and Chief Accounting Officer | December 6, 2024 | ||||||||||||
| (Agostino Ricupati) | (Principal Accounting Officer) | |||||||||||||
| /s/ COLLEEN E. JAY | Director | December 6, 2024 | ||||||||||||
| (Colleen E. Jay) | ||||||||||||||
| /s/ CYNTHIA L. LUCCHESE | Director | December 6, 2024 | ||||||||||||
| (Cynthia L. Lucchese) | ||||||||||||||
| /s/ LAWRENCE KURZIUS | Director | December 6, 2024 | ||||||||||||
| (Lawrence Kurzius) | ||||||||||||||
| /s/ MARIA RIVAS M.D. | Director | December 6, 2024 | ||||||||||||
| (Maria Rivas M.D.) | ||||||||||||||
| /s/ TERESA S. MADDEN | Director | December 6, 2024 | ||||||||||||
| (Teresa S. Madden) |
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
CORPORATE INFORMATION
| BOARD OF DIRECTORS Weiss, Robert S. Chairman of the Board Jay, Colleen E. Director Kozy, William A. Director Kurzius, Lawrence Director Lucchese, Cynthia L. Director Madden, Teresa S. Director Rivas, Maria, M.D. Global Chief Medical Officer for Specialty and Primary Care and Head, Evidence Generation, Pfizer, Inc. White, Albert G., III President & Chief Executive Officer COMMITTEES OF THE BOARD Audit Committee Madden, Teresa S. (Chairman) Kurzius, Lawrence Lucchese, Cynthia L. Rivas, Maria, M.D. Corporate Governance and Nominating Committee Lucchese, Cynthia L. (Chairman) Jay, Collen E. Kozy, William A. Rivas, Maria, M.D. Organization and Compensation Committee Jay, Colleen E. (Chairman) Kozy, William A. Kurzius, Lawrence Madden, Teresa S. | EXECUTIVE OFFICERS White, Albert G., III President and Chief Executive Officer McBride, Daniel G. Executive Vice President and Chief Operating Officer Andrews, Brian G. Executive Vice President, Chief Financial Officer and Treasurer Ricupati, Agostino Senior Vice President and Chief Accounting Officer Khadder, Nicholas S. Vice President, General Counsel and Corporate Secretary Sheffield, Holly R. President of CooperSurgical, Inc. Warner, Gerard H., III President of CooperVision, Inc. PRINCIPAL SUBSIDIARIES CooperVision, Inc. 6101 Bollinger Canyon Road Suite 500 San Ramon, CA 94583 925-460-3600 www.coopervision.com CooperSurgical, Inc. 75 Corporate Drive Trumbull, CT 06611 203-601-5200 www.coopersurgical.com CORPORATE OFFICES The Cooper Companies, Inc. 6101 Bollinger Canyon Road Suite 500 San Ramon, CA 94583 925-460-3600 www.coopercos.com | INVESTOR INFORMATION Recent news releases, the annual report on Securities and Exchange Commission Form 10-K, information about the Company's corporate governance program, recent investor presentations, replays of quarterly conference calls and historical stock quotes are available on our Web site at www.coopercos.com. INVESTOR RELATIONS CONTACT Kim Duncan Vice President, Investor Relations and Risk Management 6101 Bollinger Canyon Road Suite 500 San Ramon, CA 94583 Voice: 925-460-3663 E-mail: ir@cooperco.com ANNUAL MEETING The Cooper Companies will hold its Annual Stockholders' Meeting in April 2025. TRANSFER AGENT Equiniti Trust LLC 48 Wall Street, Floor 23 New York, NY 10005 800-937-5449 TRADEMARKS CooperVision, CooperSurgical, and other trade names, trademarks or service marks of CooperCompanies and its subsidiaries appearing in this report are the property of CooperCompanies and its subsidiaries. Trade names, trademarks and service marks of the other companies appearing in this report are the property of their respective holders. INDEPENDENT AUDITORS KPMG LLP STOCK EXCHANGE LISTING Nasdaq Global Select Market Ticker Symbol “COO” |
Previous: Item 15. Exhibits and Financial Statement Schedules.